Abstract: Provided are formulations and methods for treating inflammatory bowel disease, including Crohn's disease, ulcerative colitis, and Johne's disease. The formulations provided comprise pharmaceutically acceptable gallium compounds; the methods provided comprise means of using such formulations in the treatment of inflammatory bowel disease and closely related disorders.

Abstract: Provided are complexes of gallium and polyalcohols. Also provided are pharmaceutical compositions comprising such complexes and methods of their use. Methods of preparing the complexes are also provided.

Abstract: A GFCI having a fault indicator device or signaling device that provides a continuous audible/visual indication of a failure condition of the GFCI is disclosed herein. A failure condition may occur when continuous current flows through the terminals of a trip coil caused by a failed or damaged component such as a TRIAC or SCR of a GFCI. The failure indicator is coupled across the trip coil in the trip mechanism thereby allowing the indicator to detect the current flow. By placing such a visual and/or audible signaling device across the trip coil terminals, the shorted TRIAC or SCR provides continuous power to the coil terminals and the signaling device, even after the coil has burned out, thereby reminding a user to replace the GFCI receptacle. The signaling device can be implemented as an LED, neon lamp, buzzer or other device.

Abstract: Provided are compositions and methods to treat liver cancer and related disorders in human or veterinary individuals. Primary liver cancers, including those metastatic to other parts of the body, as well as cancers metastatic to the liver cancer, can be treated and/or prevented with the compositions and methods of the present invention. The methods comprise the administration of pharmaceutically acceptable gallium compositions, including gallium maltolate. Routes of administration include, without limitation, oral, intravenous, intratumoral, and into blood vessels as part of chemoembolization therapy. Some of the compositions and methods disclosed herein are applicable to cancers other than liver cancer.

Abstract: A bone fixation device includes a rod including a first portion extending from a proximal side of the rod, and a second portion extending from the first portion, wherein the rod is inserted into a medullary canal of an ulna bone, the first portion includes a plurality of longitudinally displaced screw holes, having axes whereby at least two screws inserted into the screw boles extend in discrete directions into a metaphyseal portion of the ulna. The bone fixation device also includes a curved extension portion extending from the proximal side of the rod to capture an olecranon of the ulna. The device provides the benefits of an intramedullary nail and proximal tension band type fixation in a single device. The fixation device permits a minimally invasive treatment of proximal ulna fractures that may otherwise be under treated.

Abstract: Resettable circuit interrupting devices, such as GFCI devices, that include reset lockout portion that does not test the circuit interrupter are provided. A resettable circuit interrupting device, such as a GFCI device that includes a reset lockout portion that prevents the reestablishing of electrical continuity if the circuit interrupting portion is non-operational. More specifically, there is disclosed a circuit interrupting portion which prevents the armature of a solenoid from moving if the solenoid overheats.

Abstract: A GFCI having a fault indicator device or signaling device that provides a continuous audible/visual indication of a failure condition of the GFCI is disclosed herein. A failure condition may occur when continuous current flows through the terminals of a trip coil caused by a failed or damaged component such as a TRIAC or SCR of a GFCI. The failure indicator is coupled across the trip coil in the trip mechanism thereby allowing the indicator to detect the current flow. By placing such a visual and/or audible signaling device across the trip coil terminals, the shorted TRIAC or SCR provides continuous power to the coil terminals and the signaling device, even after the coil has burned out, thereby reminding a user to replace the GFCI receptacle. The signaling device can be implemented as an LED, neon lamp, buzzer or other device.

Abstract: Resettable circuit interrupting devices, such as GFCI devices, that include reset lockout portion that does not test the circuit interrupter are provided.

Abstract: As disclosed in U.S. Pat. No. 6,246,558; there is disclosed resettable circuit interrupting devices, such as GFCI devices, that include a reset lockout portion that prevents the reestablishing of electrical continuity if the circuit interrupting portion is non-operational. There is here disclosed a circuit interrupting portion which prevents the armature of a solenoid from moving if the circuit interrupting portion is not operational.

Abstract: Resettable circuit interrupting devices, such as GFCI devices, that include reset lockout portion that does not test the circuit interrupter are provided.

Abstract: Resettable circuit interrupting devices, such as GFCI devices, that include reset lockout portion that does not test the circuit interrupter are provided.

Abstract: Disclosed are pharmaceutical compositions that comprise gallium complexes of 3-hydroxy-4-pyrones. These compositions provide enhanced gallium bioavailability particularly when orally administered as compared to the gallium bioavailability achieved by use of pharmaceutical compositions containing gallium salts. Compositions included in this invention are useful in providing gallium to humans and other mammals for a wide variety of medical and veterinary applications, including the treatment, prevention, or diagnosis of hypercalcemia, certain cancers, certain disorders of calcium homeostasis, and certain bone diseases including osteoporosis, osteopenia, and Paget's disease.

Abstract: The subjects of this invention are pharmaceutical compositions that comprise gallium complexes of 3-hydroxy-4-pyrones. The compositions have been developed to provide pharmaceutically acceptable gallium bioavailability together with low toxicity, particularly for oral administration. Compositions included in this invention should be useful in providing gallium to humans and other animals for a wide variety of medical and veterinary applications, including the treatment, prevention, or diagnosis of certain bone diseases, certain cancers, and certain disorders of calcium homeostasis.

Abstract: Disclosed are pharmaceutical compositions that comprise gallium complexes of 3-hydroxy-4-pyrones. These compositions provide enhanced gallium bioavailability particularly when orally administered as compared to the gallium bioavailability achieved by use of pharmaceutical compositions containing gallium salts. Compositions included in this invention are useful in providing gallium to humans and other mammals for a wide variety of medical and veterinary applications, including the treatment, prevention, or diagnosis of hypercalcemia, certain cancers, certain disorders of calcium homeostasis, and certain bone diseases including osteoporosis, osteopenia, and Paget's disease.

Abstract: Disclosed are pharmaceutical compositions that comprise gallium complexes of 3-hydroxy-4-pyrones. These compositions provide enhanced gallium bioavailability particularly when orally administered as compared to the gallium bioavailability achieved by use of pharmaceutical compositions containing gallium salts. Compositions included in this invention are useful in providing gallium to humans and other mammals for a wide variety of medical and veterinary applications, including the treatment, prevention, or diagnosis of hypercalcemia, certain cancers, certain disorders of calcium homeostasis, and certain bone diseases including osteoporosis, osteopenia, and Paget's disease.

Abstract: Disclosed are pharmaceutical compositions that comprise gallium complexes of 3-hydroxy-4-pyrones. These compositions provide enhanced gallium bioavailability particularly when orally administered as compared to the gallium bioavailability achieved by use of pharmaceutical compositions containing gallium salts. Compositions included in this invention are useful in providing gallium to humans and other mammals for a wide variety of medical and veterinary applications, including the treatment, prevention, or diagnosis of hypercalcemia, certain cancers, certain disorders of calcium homeostasis, and certain bone diseases including osteoporosis, osteopenia, and Paget's disease.

Abstract: The subjects of this invention are pharmaceutical compositions that comprise gallium complexes of 3-hydroxy-4-pyrones. The compositions have been developed to provide pharmaceutically acceptable gallium bioavailability together with low toxicity, particularly for oral administration. Compositions included in this invention should be useful in providing gallium to humans and other animals for a wide variety of medical and veterinary applications, including the treatment, prevention, or diagnosis of certain bone diseases, certain cancers, and certain disorders of calcium homeostasis.

Abstract: Disclosed are pharmaceutical compositions that comprise gallium complexes of 3-hydroxy-4-pyrones. These compositions provide enhanced gallium bioavailability particularly when orally administered as compared to the gallium bioavailability achieved by use of pharmaceutical compositions containing gallium salts. Compositions included in this invention are useful in providing gallium to humans and other mammals for a wide variety of medical and veterinary applications, including the treatment, prevention, or diagnosis of hypercalcemia, certain cancers, certain disorders of calcium homeostasis, and certain bone diseases including osteoporosis, osteopenia, and Paget's disease.

Abstract: A chewing gum containing an appetite suppressant quantity of chromic picolinate.

Abstract: Releasable dental impression tray has a top member, a side member and a handle. The tray has a compressible spring for compressing resilient impression material after it has set to facilitate removal of the tray.